Similar articles

• Background and rationale of the eXalt3 trial investigating X-396 in the treatment of ALK+ non-small-cell lung cancer.

  Singhi EK, Horn L. Singhi EK, et al. Future Oncol. 2018 Aug;14(18):1781-1787. doi: 10.2217/fon-2017-0619. Epub 2018 Mar 6. Future Oncol. 2018. PMID: 29506392 Review.
• [Virtual bronchoscopy].

  Rogalla P, Rückert JC, Schmidt B, Witt C, Meiri N, Hamm B. Rogalla P, et al. Radiologe. 2001 Mar;41(3):261-8. doi: 10.1007/s001170050986. Radiologe. 2001. PMID: 11322072 Review. German.
• Pre-clinical validation of virtual bronchoscopy using 3D Slicer.

  Nardelli P, Jaeger A, O'Shea C, Khan KA, Kennedy MP, Cantillon-Murphy P. Nardelli P, et al. Int J Comput Assist Radiol Surg. 2017 Jan;12(1):25-38. doi: 10.1007/s11548-016-1447-7. Epub 2016 Jun 21. Int J Comput Assist Radiol Surg. 2017. PMID: 27325238
• Complete pathologic response in soft tissue sarcoma lung metastases with pazopanib.

  Eroglu Z, Kim J, Wilczynski S, Chow WA. Eroglu Z, et al. J Thorac Oncol. 2014 Jan;9(1):e4-6. doi: 10.1097/JTO.0b013e3182a4700d. J Thorac Oncol. 2014. PMID: 24346105 No abstract available.
• Imatinib mesylate inhibits the growth of metastatic lung lesions in a patient with dermatofibrosarcoma protuberans.

  Mizutani K, Tamada Y, Hara K, Tsuzuki T, Saeki H, Tamaki K, Matsumoto Y. Mizutani K, et al. Br J Dermatol. 2004 Jul;151(1):235-7. doi: 10.1111/j.1365-2133.2004.06024.x. Br J Dermatol. 2004. PMID: 15270901 Review. No abstract available.